Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Loredana Santo, Teru Hideshima, Andrew L. Kung, +16

Blood

Ricolinostat (<scp>ACY</scp>‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death

Yuko Mishima, Loredana Santo, Homare Eda, +11

British Journal of Haematology

Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease

Homare Eda, Loredana Santo, Marc N. Wein, +9

Journal of Bone and Mineral Research

Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma

Ka Tat Siu, Janani Ramachandran, Andrew J. Yee, +7

Leukemia

Hematological MalignancyNovel Small-molecule BromodomainMedicineExtra-terminal Protein InhibitorImmunology +6

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma

Samantha Pozzi, Mariateresa Fulciniti, Yan Hua, +13

Bone

Hematological MalignancyImmunologyImmune Checkpoint InhibitorAutoimmunityMultiple Myeloma +4

Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs

Diana Cirstea, Teru Hideshima, Loredana Santo, +13

Leukemia

Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy

Tyler Scullen, Loredana Santo, Sonia Vallet, +8

Leukemia

Hematological MalignancyMedicineMalignant Blood DisorderImmunologyHematology +7

A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity

Homare Eda, Loredana Santo, Diana Cirstea, +11

Leukemia

Hematological MalignancyOncologyResultant Antimyeloma ActivityMedicineImmunology +6

FGF-2 signaling induces downregulation of TAZ protein in osteoblastic MC3T3-E1 cells

Homare Eda, Katsuhiko Aoki, Keishi Marumo, +2

Biochemical and Biophysical Research Communications

Developmental BiologyBone Morphogenic ProteinFibroblast Growth FactorTaz ProteinMatrix Biology +6

Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma

Diana Cirstea, Loredana Santo, Teru Hideshima, +13

Molecular Cancer Therapeutics

Mtor Kinase InhibitionImmunologyCancer BiologyTumor BiologyMyeloid Neoplasia +17